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Summary To evaluate the diagnostic application of urinary transforming growth factor-o1 (TGF-p1) and serum a-fetoprotein (AFP) levels in
hepatocellular carcinoma (HCC), TGF-,B1 and AFP were determined in 94 patients with cirrhotic HCC and in 94 sex- and age-matched
patients with cirrhosis alone. TGF-01 and AFP levels in HCC were higher than in cirrhosis alone (P= 0.0001). There is an inverse correlation
between TGF-f1 and log AFP (r = -0.292, P = 0.004). Multivariate analysis indicated that TGF-j1 and AFP were closely associated, in a
dose-related fashion, with the development of HCC. Receiver-operating characteristic (ROC) curves were used to determine the optimal cut-
off values of TGF-01 (50 gg g-1 creatinine) and AFP (100 ng ml-'). Both TGF-p1 and AFP showed a high specificity (99%) and positive
likelihood ratio. The sensitivity was 53.1% forTGF-f1 and 55.3% forAFP. The determination of both markers in parallel significantly increased
the diagnostic accuracy (90.1%) and sensitivity (84%), with a high specificity (98%) and positive likelihood ratio (40.0). In conclusion, TGF-f1
and AFP are independent tumour markers of HCC and may be used as complementary tumour markers to discriminate HCC from cirrhosis.
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Hepatocellular carcinoma (HCC) is the seventh most common
cancer in men and the ninth most common cancer in women, with
an estimated incidence of between 250 000 and 1.2 million per
year worldwide (Kew, 1996). It is a highly malignant tumour with
a poor prognosis. The poor prognosis has been attributed to late
diagnosis. An effective screening system to detect HCC at an early
stage may result in more effective treatment. The lack of symp-
toms in the early stage ofHCC makes screening ofpatients at risk
for HCC impractical. a-Fetoprotein (AFP) is an oncofetal protein
produced by HCC. Although the role of AFP in the diagnosis of
advanced HCC is well recognized, at least one-third ofsmall HCC
and 30% of advanced HCC will be missed unless another
diagnostic tool is used (Tsai et al, 1990, 1991, 1994b, 1995;
Sherlock and Dooley, 1993; Colombo, 1995; Kew, 1996)
Furthermore, AFP may be elevated in non-malignant liver disease
(Sherlock and Dooley, 1993; Colombo, 1995; Tsai et al, 1995).
These shortcomings have limited its clinical application and moti-
vated many investigators to search for otherbetter tumour markers
for HCC.
Transforming growth factor-PI (TGF-,1) is a homodimeric
polypeptide involved in the regulation of growth and differentia-
tion of both normal and transformed cells (Roberts et al, 1988;
Robert and Sporn, 1990). Overexpression ofthe TGF-f1 gene has
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been reported in transformed cells and human malignancies
(Roberts et al, 1988; Robert and Sporn, 1990). Recently, elevated
levels ofTGF-f mRNA and its polypeptide in tissue and plasma of
human HCC have been reported (Ito et al, 1990, 1991; Shrai et al,
1992, 1994; Bedossa et al, 1995). Moreover, the plasma TGF-,1
level could be used as a marker to monitor therapy in HCC (Shrai
et al, 1992, 1994).
Transforming growth factors have been described in the urine of
healthy adults and patients (Sherwin et al, 1983; Nishimura et al,
1986; Ranganathan et al, 1987; Yeh et al, 1987; Chuang et al,
1991, 1994; Coupes et al, 1994). Transforming growth factor-a
can serve as a tumour marker and as a marker for malignant poten-
tial (Baldwin and Zhang, 1992; Lee et al, 1992; Chuang et al,
1994; Sherlock, 1994). However, the role of TGF-P1 as a diag-
nostic marker has never been clearly elucidated.
Although HCC may occasionally develop in normal liver, most
patients are associated with long-lasting chronic liverdisease (Tsai
et al, 1994a-f; Colombo, 1995). Chinese men who are carriers of
antibodies to hepatitis C virus (anti-HCV) or chronic hepatitis B
surface antigen (HBsAg) carriers have a high risk for developing
HCC, which is increased in the presence of cirrhosis and
advancing age (Jeng and Tsai, 1991; Sherlock and Dooley, 1993;
Kew, 1994; Sherlock, 1994; Tsai et al, 1994a-f, 1995, 1996a, b).
Cirrhosis is considered to be a premalignant lesion of HCC.
Between 2.2% and 55% ofautopsied cirrhotics had HCC, whereas
about 80% of HCC patients had coexisting cirrhosis (Jeng and
Tsai, 1991; Simonetti et al, 1991; Sherlock and Dooley, 1993; Tsai
et al, 1994a, c, e,J). Thus, early detection ofHCC in patients with
cirrhosis is important. This study determines the diagnostic
efficacy of TGF-,B1 and AFP for detection of HCC in cirrhotic
patients.
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SUBJECTS AND METHODS
Study population
The study population comprised 94 non-alcoholic consecutive
cirrhotic HCC patients and 94 sex-matched and age-matched
(±5 years) patients with cirrhosis alone. Cirrhosis was diagnosed
by liver biopsy, abdominal sonography (portal systemic shunts,
splenomegaly, spotty coarse parenchyma, nodular surface and dull
or round edge), biochemical evidence ofparenchymal damage plus
endoscopic oesophageal or gastric varices (Tsai et al, 1993, 1994a).
Patients were classified into the three Child-Pugh's grades based
on their clinical status (Pugh et al, 1973). Among patients with
cirrhosis alone, all 24 patients with Child-Pugh C, 20 of29 patients
with Child-Pugh B and 26 of41 patients with Child-Pugh A were
diagnosed by sonography and biochemical data plus endoscopic
varices. The remaining 24 cirrhotic patients were diagnosed histo-
logically. HCC was diagnosed by liver biopsy or aspiration
cytology. Only patients without previous history of treatment were
enrolled, and serum samples collected before treatment were used
for analysis. In patients with HCC, there were 76 men and 18
women, with ages ranging from 29 to 72 (median 58) years.
Hepatitis B surface antigen (HBsAg) was positive in 67 (71.3%)
HCC patients and another 70 (74.4%) patients with cirrhosis alone.
Antibody to hepatitis C virus (anti-HCV) was positive in 26
(27.6%) patients with HCC and 23 (24.4%) patients with cirrhosis
alone. Another 50 HBsAg-negative and anti-HCV-negative
community healthy adults were enrolled as healthy controls.
Thirty-nine ofthem were men and the other 11 were women. Their
ages ranged from 28 to 67 (median 55) years. There were no signif-
icant differences in median age and sexual distribution among these
three groups. There was no space-occupying lesion in patients with
cirrhosis alone and healthy controls as evidenced by normal
abdominal sonography. All healthy controls have normal serum
transaminase and creatinine levels. All the patients and controls
were enrolled during the same period and all gave informed consent
to participate in the study, which was approved by the Investigation
and Ethics Committee ofthe hospital.
Urine collection and preparation
The extraction ofTGF-,B1 from urine was modified from methods
described previously (Sherwin et al, 1983). Spot urine (10 ml) in
the early morning was collected and kept at 4°C. Urine specimens
were acidified with acetic acid (Sigma, St Louis, MO, USA) to a
final concentration of 1 M. The resulting precipitate of acid insol-
uble materials was removed by centrifugation at 800 g for 30 min
at 4°C. Acidified supernatants were applied to Sep-Pak C,8
cartridges (Waters, Milford, MA, USA) equilibrated with 60%
acetonitrile (Sigma) containing 0.1% trifluoroacetic acid (TFA;
Sigma). After loading the urine, the cartridge was washed slowly
(1 ml min-') with 20 ml of 0.1% TFA. TGF-5l was eluted with
60% acetonitrile containing 0.1% TFA. The extracted material was
lyophilized, dissolved in 1 ml of 1 M acetic acid. The concentrated
samples were stored at -70°C until used.
Radioimmunoassay for TGF-[1
TGF-(I was determined with TGF-[I 1251 radioimmunoassay kit
(EI du Pont de Nemours, Boston, MA, USA). The recovery of
native TGF-01 is greater than 90%. The sensitivity of the assay is
approximately 0.27 ng ml-'. The working range is between
0.3 ng ml-1 and 20 ng ml-l. The assay is highly specific, without
cross-reaction with human and porcineTGF-P2, chickenTGF-P3,
basic fibroblast growth factor and interleukins. Briefly, 10 ,l of
1.2 N hydrochloric acid (Sigma) was added to 100 g1 of prepared
urine sample. After mixing thoroughly by vortexing, the specimen
was incubated at room temperature for 15 min. Then the specimen
was neutralized by addition of20 pl of0.5 M Hepes (N-[2-hydrox-
yethyl] piperazine-N'-[2-ethanesulphonic acid]) (Sigma)/0.72 M
sodium hydroxide (Sigma). The pH was adjusted to around
7.0-8.0. After mixing thoroughly by vortexing, 100 gl of the
prepared specimens (or different concentrations of standard
TGF-,1) were added to 100 gl of anti-human TGF-31 antibody.
The mixture was mixed and incubated at room temperature for6 h.
One hundred microlitres of[125I]TGF-PI was added and incubated
at room temperature for 18 h. After adding 100 pl of second anti-
body, the mixture was incubated for 1 h at room temperature. Then
the tubes were centrifuged at 2200 g at 4°C for 30 min.
Radioactivity in the pellet was counted in a gamma-counter.
Urinary creatinine, determined by autoanalyser, was used to
normalize the urinary TGF-,1 level. The final concentration of
TGF-f1 was expressed as jug g-' creatinine. The coefficients of
variation of intra-assay and inter-assay were 7.5% and 10.0%
respectively.
Serological examination
HBsAg, anti-HCV and AFP were tested with Ausria-I1, second-
generation HCV enzyme immunoassay (EIA) and a-feto
RIABEAD (Abbott Laboratories, Chicago, IL, USA) respectively.
For anti-HCV, reactive specimens were retested. Repeatedly reac-
tive samples were tested with another second-generation anti-HCV
immunoassay (UBI HCV EIA; United Biomedical, Lake Success,
NY, USA), which incorporates synthetic peptides from the capsid
and non-structural protein region as the solid-phase antigen. Only
specimens reactive in all three tests were considered as anti-HCV
positive. Conventional liver function tests and creatinine level
were determined with an autoanalyser.
Statistical analysis
The Mann-Whitney U-test was used to compare the difference
between medians ofcontinuous variable. The relationship between
continuous variables was analysed by Spearman rank correlation.
Chi-square test with Yates' correction was used to compare
proportions. Stepwise logistic regression was used for multivariate
analysis. Odds ratio (OR) with 95% confidence interval (95% CI)
was used to estimate causal relations between risk factors and
exposure. Two-tailed P-values and 95% CI were given when
appropriate. An alpha of 0.05 was used as the indicator of statis-
tical significance.
The calculation of sensitivity, specificity, positive and negative
predictive value, positive andnegative likelihood ratio anddiagnostic
accuracy were calculated according to the following formula (Sox et
al, 1989): sensitivity =aI(a+c); specificity = dl(b + d); accuracy = (a
+ d)/(a + b + c + d); positive predictive value =
a/(a + b); negative predictive value = dl(c + d); positive likelihood
ratio = sensitivity/(l-specificity); negative likelihood ratio =
(1-sensitivity)/specificity; a = true-positive cases; b = false-positive
cases; c = false-negative cases; d = true-negative cases.
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Receiver-operating characteristic (ROC) curves and likelihood
ratios were used to quantitate and compare the diagnostic perfor-
mance of TGF-01 and AFP. ROC curves were constructed by
calculating the sensitivities and specificities of AFP or TGF-P1
assays at several cut-offpoints. The cut-off value with the highest
accuracy was selected as diagnostic cut-offpoint. Ifmore than one
cut-off value showed the same accuracy, the cut-off value with
nearly equal sensitivity and specificity was chosen. The difference
in diagnostic accuracy between the marker tests were measured by
McNemar's X2 test. The area under ROC curve and all the statis-
tical analyses were performed with BMDP/Dynamic, release 7.0
(BMDP Statistical Software, Los Angeles, CA, USA).
RESULTS
Urinary TGF-31 and serum AFP levels in patients and
healthy controls
As shown in Table 1, both urinary TGF- Il and serum AFP levels
in patients with HCC were significantly higher than in cirrhotic
patients alone (each P = 0.0001) or in healthy controls (each
P = 0.0001). The median levels ofurinaryTGF-P1 and serum AFP
in patients with cirrhosis alone were also statistically higher than
those ofhealthy controls (P = 0.0001). When patients were classi-
fied by Child-Pugh scores (Pugh et al, 1973), TGF-131 levels in
patients (HCC orcirrhosis alone) with Child-Pugh C were signifi-
cantly higher than those in patients with Child-Pugh B or patients
with Child-Pugh A (data not shown).
The upper limit of normal AFP level was defined as 20 ng ml-1
(Sherlock and Dooley, 1993; Kew, 1996), whereas the recom-
mended diagnostic cut-off value for HCC was 400 ng ml-1
(Colombo, 1995). A serum AFP level less than 20 ng ml-1 was
noted in all healthy controls, 81 (86.1%) patients with cirrhosis
alone and 33 (35.1%) patients with HCC. There were 45 (47.8%)
HCC patients with AFP greater than 400 ng ml-' (Table 1).
As shown in Figure 1, there was an inverse correlation between
log AFP and TGF-,B1 levels (r = -0.292, P = 0.004). The median
level of TGF-P1 (66.4; range 6.0-184.0 gg g-1 creatinine) in 33
HCC patients with normal AFP level was significantly higher than
that (36.4; range 3.5-153.0 jg g-' creatinine) in patients with
higher AFP level (P = 0.024).
TGF-,1 and AFP as independent tumour markers of
HCC
In order to adjust the influence ofsex, age and impaired liverfunc-
tion on TGF-P1 and AFP levels, stepwise logistic regression was
used for multivariate analysis. The dependent variable was the
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Figure 1 The relationship between levels of serum log AFP and urinary
TGF-j 1 in 94 patients with cirrhotic hepatocellular carcinoma. The horizontal
broken line indicates normal AFP level (20 ng ml-'). r, coefficient of
correlation; log AFP, logarithm of a-fetoprotein based on 10; TGF-fl 1,
transforming growth factor-5 1
status of HCC existence. The independent variables included
TGF-,1, AFP, sex, age, albumin, globulin, direct and indirect
bilirubin, transaminase, alkaline phosphatase and y-glutamyl-
transpeptidase. The results indicate that both TGF-,31 (OR 1.08,
95% CI 1.04-1.12, P = 0.001) and AFP (OR 1.06, 95% CI
1.02-1.10, P = 0.001) are associated, in a dose-related fashion,
with an increased risk for developing HCC.
Urinary TGF-41 and serum AFP levels in relation to
tumour size
The echogenic appearance of HCC may take three forms -
nodular, massive (> 5 cm in diameter) or diffuse (infiltrating type
with ill-defined margins) (Kew, 1996). As shown in Table 2, TGF-
01 level in patients with diffuse HCC was higher than that in
patients with non-diffuse HCC (P = 0.001). Among patients with
non-diffuse HCC, the TGF-,B1 level in patients with tumour size
less than 3 cm was lower than that in patients with larger tumours
(P = 0.018). There was no correlation between tumour size and
serum AFP level. Among patients with diff-use type HCC, the
TGF-,1 level in 15 patients with Child-Pugh C (median 129.5;
range 3.5-184.0 jg g-' creatinine) was higher than that (median
60.4; range 12.0-177.4 jig g-' creatinine) in patients with
Child-Pugh A and Child-Pugh B (P = 0.026).
Table 1 Urinary TGF-,B 1 and serum AFP levels in patients with cirrhosis and cirrhotic hepatocellular carcinoma and in
healthy control subjects
Subjects n TGF-f1 (tg g-1 creatinine) AFP (ng ml-1) AFP (ng ml-')
Median (range) Median (range) < 20 21-399 . 400
HCC 94 61.1 (3.5-184.0) 155.0 (3.0-965 000) 33 16 45
Cirrhosis 94 30.3 (4.3-52.5) 4.0 (3.0-107) 81 13 0
Control 50 12.2 (1.5-33.6) 3.0 (3.0-10.0) 50 0 0
P-value (Mann-Whitney U-test) for HCC vs cirrhosis = 0.0001 forTGF-j 1 and AFP; for HCC vs control = 0.0001 for TGF-, 1
and AFP; and for cirrhosis vs control = 0.0001 forTGF-jl 1 and AFR TGF-,3 1, transforming growth factor ,B 1; AFP,
a-fetoprotein; HCC, hepatocellular carcinoma.
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Table 2 Echographic type and size of HCC in relation to urinary TGF-j 1 and
serum AFP levels
Type and size of HCC AFP (ng ml-') TGF-pl (jg g-' creatinine)
Diffuse (n = 30) 125 (3-965000)a 96.5 (3.5-184.0)b
Non-diffuse (n = 64) 342 (3-282000) 33.3 (5.0-164.3)b
< 3 cm (n = 19) 170 (3-53095) 17.0 (5.0-112.3)c
> 3 cm (n = 45) 1490 (3-282 000) 56.9 (5.0-164.3)c
TGF-f 1, transforming growth factor ,B 1; AFP, a-fetoprotein; HCC,
hepatocellular carcinoma. aData are expressed as median with ranges in
parentheses. bp= 0.001 (Mann-Whitney U-test). cp = 0.018 (Mann-Whitney
U-test).
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TGF-p1 and AFP as diagnostic markers for HCC
evaluated by ROC curves
As TGF-31 and AFP were significantly associated with the devel-
opment of HCC, an attempt was made to differentiate cirrhotic
HCC from cirrhosis alone by these two markers. Figure 2 shows
ROC curves forTGF-,B1 and AFP. The calculated area under ROC
curve was 0.801 for AFP and 0.730 forTGF-p1. The sensitivity of
each marker was determined at several specificity levels. The
corresponding sensitivities and actual cut-off points of the data
shown in Figure 1 are given in Table 3. The optimal cut-offvalues
selected by ROC curves were 50 ,ug g-' creatinine forTGF-P1 and
100 ng ml-" for AFP. Table 4 shows the calculated sensitivities,
specificities, accuracies, positive and negative predictive values,
positive and negative likelihood ratios. According to the ROC
curve analysis, the optimal cut-off level for AFP was 100 ng ml-',
as up to this level the specificity improved without essentially
decreasing the sensitivity. The resulting specificity was 98.9% and
sensitivity 55.3%, with a diagnostic accuracy of 77.6%, positive
andnegative likelihoodratios of50.2 and0.45 respectively (Table4).
On the other hand, the recommended diagnostic level of AFP for
HCC was 400 ng ml-1 (Colombo, 1995). Using 400 ng ml as cut-
off value, the sensitivity decreased to 47.8%, the specificity
increased to 100%. There was no significant difference between
the diagnostic accuracies calculated from these two cut-offvalues.
In the ROC curve analysis, the optimal cut-off value for TGF-,B1
(50 jig g-' creatinine) gave a specificity of 98.9% at sensitivity
0 0.2
1-Specificity
Figure 2 The value of serum AFP and urinary TGF-,B 1 in the diagnosis of
HCC among 94 patients with cirrhotic HCC and 94 patients with cirrhosis
alone as analysed with ROC curves. The area under ROC curve was 0.801
for AFP (m) and 0.730 for TGF-. 1 (0)
level of 53.1%. The calculated diagnostic accuracy, positive and
negative likelihood ratios were 76.0%, 48.22 and 0.47 respectively
(Table 4). Regardless of the marker used, there was no significant
difference in the diagnostic accuracies, as also reflected in the area
under ROC curves.
When both AFP and TGF-,1 were determined in parallel, 27
(64.2%) of 42 HCC patients with AFP < 100 ng ml-' and 30
(61.2%) of 49 HCC patients with AFP < 400 ng ml-' could be
diagnosed. The resulting sensitivity is 84.0% with a diagnostic
accuracy of90.1% using AFP = 100 ng ml' as cut-offpoint and a
sensitivity of 79.7% with a diagnostic accuracy of 81.3% using
AFP = 400 ng ml' as cut-offpoint. In either condition, the speci-
ficity is up to 99%, with apositive likelihood ratio of40.0 and 74.5
and a negative likelihood ratio of 0.16 and 0.20 respectively
(Table 4). As shown in Table 4, the diagnostic accuracies ofusing
both AFP and TGF-,B1 as markers were significantly higher than
using either marker alone (P < 0.001).
Table 3 The sensitivities and corresponding cut-off values and diagnostic accuracies for urinary TGF-,3 1 and serum
AFP in the detection of HCC at specificity levels between 40% and 100%
Specificity (%)
100 98.9 90 80 70 60 50 40
AFP
Sensitivity (%) 47.8 55.3 63.8 69 75.5 78.7 86 88.3
Cut-off (ng ml-1) 400 1O0a 28 16 12 7 4 3
Accuracy (%) 73.9 77.6 77.1 75 72.8 69.6 68.1 63.8
TGF-P 1
Sensitivity (%) 51 53.1 55.3 55.3 57.4 57.5 64.9 88.3
Cut-off (jg g-1 creatinine) 58.5 50a 43 40 36 34.5 31 11
Accuracy (%) 75.5 76.0 72.3 68.6 63.3 60 57.5 54.3
TGF-1 1, transforming growth factorf1; AFP, a-fetoprotein; HCC, hepatocellular carcinoma. aThe optimal cut-off value
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Table 4 Urinary TGF-J 1 and serum AFP as diagnostic markers of HCC evaluated by using ROC curve
Markersa Sensitivity (%) Specificity (%) Accuracy (%) Predictive value (%) Likelihood ratio
Positive Negative Positive Negative
A 53.1 98.9 76.0b,e 98.0 67.8 48.2 0.47
B 55.3 98.9 77.6c 98.1 68.8 50.2 0.45
C 47.8 100 73.9d 100 65.7 > 47.8f 0.52
A or B 84.0 97.8 90.1b,c 97.5 85.9 40.0 0.16
A or C 79.7 98.9 81.3d.e 98.6 83.0 74.5 0.20
aCut-off values (A, TGF-,B 1 2 50 ig g-1 creatinine; B, AFP 2 100 ng ml-'; C, AFP .400 ng ml-') were determined by ROC curves
b,c.dep < 0.001 (MacNemar X2 test). fCalculated by using specificity > 99%.
DISCUSSION
The liver is the major site ofclearance and metabolism ofbiologi-
cally active TGF-,B1 (Roberts and Sporn, 1990). Raised TGF-P1
level may be caused by increased production and/or decreased
clearance. An increased TGF-P1 production has been reported
after hepatectomy and in some cases of liver disease (Ito et al,
1990, 1991; Roberts and Sporn, 1990; Shrai et al, 1992, 1994;
Bedossa et al, 1995). In this study, the raised TGF-,1 level in
patients with cirrhosis alone might be caused by impaired liver
function (Table 1). Elevated urinary TGF-, 1 level in patients with
cirrhotic HCC might be due to decreased clearance and/or
increased production. The association between raised TGF-,B1
level and worsening Child-Pugh grades in patients with cirrhotic
HCC or cirrhosis alone suggests the contribution ofimpaired liver
function (Tsai et al, 1997b-d). After adjusting for possible
confounding effects caused by impaired liver function, our result
indicates that urinary TGF-,B1 level is significantly associated, in a
dose-related fashion, with the development ofHCC. In addition, a
larger tumour was frequently associated with a higher TGF-41
level (Table 2). The significantly decreased TGF-31 level after
complete anti-cancer treatment in patients with HCC (Shrai et al,
1992, 1994; Tsai et al, unpublished observation) also implies that
TGF-,B1 might relate to tumour mass and that raisedTGF-P 1 level
in HCC is caused by increased production.
In diffuse-type HCC, the level of TGF-f1 is much higher than
non-diffuse type, but AFP is not (Table 2). In general, the patients
with diffuse-type HCC have much poorer liver function. Several
investigators have reported that the level of hepatic TGF-fi1
mRNA or TGF-P1 correlated with the degree of liver fibrosis and
poor liver function in patients with cirrhosis (Castilla et al, 1991;
Nagy et al, 1991; Bissell and Maher, 1996). In our study, the
TGF-,B1 level in patients with diffuse-type HCC also correlated
with worsening Child-Pugh classification. After adjusting for
confounding effects ofimpaired liver function, the result still indi-
cates that raised urinary TGF-31 was due to increased production
by HCC (data not shown). Previous reports indicate that HCC cells
produce TGF-P1 Ito et al, 1990, 1991; Shirai et al, 1992, 1994;
(Bedossa et al, 1995). TGF-,B1 released from HCC cells appears to
be an inactive form (Roberts and Spom, 1990; Shirai et al, 1992,
1994; Bedossa et al, 1995). TGF-1I may be activated with acidi-
fication, proteolysis or chaotropic agents (Roberts and Sporn,
1990; Bedossa et al, 1995). In this study, we have detected an
active form of TGF-PI by acidification in the urine of patients
with HCC.
HCC appears to be associated with hepatitis B and C virus
infection and is common in patients with cirrhosis caused by
chronic viral hepatitis (Jeng and Tsai, 1991; Sherlock and Dooley,
1993; Tsai et al, 1993, 1994a-f, 1995, 1996a,b, 1997a). Thus,
early detection of HCC in cirrhotic patients is important. During
recent years, various serological markers have been developed in
the diagnosis ofHCC (Maussier et al, 1990; Tsai et al, 1990, 1991,
1995; Fujiyama etal, 1992; Sherlock and Dooley, 1993; Chuang et
al, 1994; Colombo, 1995). Serum AFP is one of the most inten-
sively studied tumourmarkers. By ROC curve analysis, the normal
AFP is 5.2 ng ml-' (Massier et al, 1990). In cirrhotic patients with
AFP values higher than 18.5 ng ml-', the likelihood ofHCC being
present is 95% (Massier et al, 1990). Previously, we suggested a
cut-off value of 120 ng ml-', determined by ROC curve analysis,
fordiagnosis ofHCC in cirrhotic liver (Tsai et al, 1995). The diag-
nostic cut-off value of AFP for HCC is 400 ng ml-' (Colombo,
1995). As shown in this study, AFP levels less than 400 ng ml-'
were noted in 52.1.% (49/94) of HCC patients at the time of
tumour detection. Furthermore, at least one-third of small HCCs
and up to 30% ofadvanced HCC will be missed unless other diag-
nostic tools are used (Sherlock and Dooley, 1993; Colombo, 1995;
Tsai et al, 1995, 1997c,d). In addition, AFP may be elevated in
non-malignant liver disease (Sherlock and Dooley, 1993;
Colombo, 1995; Tsai et al, 1995). It is obvious that AFP alone is
not a reliable indicator for the detection ofHCC in patients with a
low AFP value. Therefore, additional and more sensitive diag-
nostic tools must be sought.
Based on the significant difference in TGF-,1 level between
patients with cirrhotic HCC and patients with cirrhosis alone, and
the close association between TGF-PI level and development of
HCC, an attempt was made to differentiate HCC from cirrhosis by
TGF-,1. Forclinical decision-making, the selected cut-offvalue of
a laboratory test should provide the best diagnostic performance
for either ruling out or ruling in the particular disease. The ROC
curve analysis is a graphic method that can be used to determine
this optimal cut-off level. In addition, it is a precise and valid
measure ofdiagnostic accuracy (Swets, 1988). The calculated area
under ROC curve ofAFP (0.801) andTGF-pI (0.730) in this study
are between 0.7-0.9, which indicates that both accuracies are
useful fordiagnostic purposes (Swets, 1988). Based on the selected
optimal cut-off value by ROC curve analysis, both TGF-,B1 and
AFP showed agood specificity, moderate sensitivity and high posi-
tive likelihood ratio (Table 4). There was no significant difference
between their diagnostic accuracies. However, determination of
AFP and TGF-41 in parallel significantly improved the diagnostic
accuracy and sensitivity without essentially decreasing the speci-
ficity (Table 4). Although each test may not have sufficient
sensitivity, the simultaneous use of both tests may be highly
discriminatory in the detection of HCC. However, parallel
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detection ofboth markers increases the number oftests performed,
which must have cost implications. So, we suggest that assay for
urinary TGF-,B should be performed to improve the detection of
HCC with low AFP production.
AFP is an oncofetal protein produced by HCC. Although the AFP
gene was re-expressed in hepatoma cells, TGF-jI may repress the
AFP gene expression in hepatoma cells (Nakao et al, 1991). Our
results also show a reverse relationship between levels ofserum AFP
and urinary TGF-j1. Theurinary TGF-[31 level in HCC patients with
normal AFP level was statistically higher than that in patients with
raised AFP. This significantly inverse trend still existed even when a
higher cut-offvalue ofAFP (100 or400 ng ml-') was used (data not
shown). This observation also favours the use of urinary TGF-PI
as a complementary tumour marker for the detection of HCC in
AFP-non-producing tumours.
As TGF-41 is a major fibrogenic factor, an increase of urinary
TGF-,B might be expected in patients with active cirrhosis (with
necroinflammatory histological features) by comparison with
non-active cirrhosis in the absence of HCC (Castilla et al, 1991;
Shrai et al, 1994; Bissell and Maher, 1996). In our patients with
cirrhosis alone, there is an association between raised TGF-j1
level and worsening Child-Pugh grades. Our result supports the
previous observation that TGF-3 1 correlates with disease activity
in cirrhosis (Castilla et al, 1991; Nagy et al, 1991). However, such
elevations may have an important effect upon the specificity of
the tests. In this study, urinary TGF-01 levels greater than the
selected cut-off points were found in 53.1% (50/94) of patients
with HCC, 1.1% (1/94) of patients with cirrhosis alone (Tables 3
and 4) and none of the healthy controls (data not shown). It is of
note that the only patient with cirrhosis alone and TGF-4H level
above the cut-off value is a patient with Child-Pugh C. In addi-
tion, elevation of AFP may be seen in patients with 'active' liver
disease (Sherlock and Dooley, 1993; Tsai et al, 1994b, 1995;
Colombo, 1995). On the other hand, the major aim of ideal
tumour marker estimation in HCC is as a means ofearly detection
(surveillance), particularly in the higher risk group. The present
analysis has looked at a population of patients with a histologi-
cally proven diagnosis of HCC. It may be assumed that many
of these had advanced disease and thus a high proportion would
have significantly elevated tumour marker levels. The high speci-
ficity and sensitivity attained might therefore be overestimating
the value of these tests as a surveillance tool. For example,
although the median level of TGF-P1 in small HCCs (< 3 cm)
was lower than the selected cut-off value (Table 2), 42.1% (8/19)
of patients with small HCCs had TGF-1I levels greater than
the selected cut-off value. This observation suggests the potential
of TGF- 1 in the early diagnosis of small HCCs. However, as
the number of patients with small HCCs is low, whether TGF-5l
is actually useful for early detection of HCC requires further
evaluation.
In conclusion, this study shows that urinary TGF-PI level
increases in patients with cirrhotic HCC. Raised urinary TGF-4I
level is closely associated with development ofHCC. The addition
of an assay for TGF- 1 to that for AFP gives a significant
improvement in detection of HCC with low AFP production.
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